Related Experiment Video
Updated: Sep 25, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer
Hirofumi Sonoda1, Chieko Kitamura2, Kuniyuki Kano3
1Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan; sonodah-sur@h.u-tokyo.ac.jp.
Lysophosphatidylinositol (LPI) and lysophosphatidylserine (LPS) were significantly elevated in ulcerative colitis (UC)-associated colorectal cancer. These phospholipid changes may play a key role in colitis-associated cancer development.
Area of Science:
- Gastroenterology
- Oncology
- Biochemistry
Background:
- Phospholipid mediators are crucial in cancer development, microenvironment, and metastasis.
- Liquid chromatography-tandem mass spectrometry (LC-MS/MS) enables sensitive phospholipid quantification from small samples.
- Previous studies utilized MS for colorectal cancer; this study extends it to ulcerative colitis (UC) and associated cancers.
Purpose of the Study:
- To investigate specific lysophospholipid changes in ulcerative colitis (UC) and UC-related colorectal cancer.
- To clarify the role of lysophospholipids in colitis-associated carcinogenesis.
Main Methods:
- Collected tissues from UC-associated colorectal cancer (n=3) and sporadic colorectal cancer (n=11).
- Quantified lysophospholipids using LC-MS/MS after tissue extraction.
- Specifically measured lysophosphatidylserine (LPS) and lysophosphatidylinositol (LPI) molecular species.
Main Results:
- Lysophosphatidylinositol (LPI) increased 3.8-fold and lysophosphatidylserine (LPS) increased 3.5-fold in UC-related colorectal cancer compared to normal mucosa.
- Specific LPI species (18:0, 16:0, 20:4) and LPS species (18:0, 22:6) were significantly elevated.
- Lysophospholipids were generally increased in colorectal cancer tissues.
Conclusions:
- Lysophospholipid levels are elevated in both colorectal cancer and UC-associated colorectal cancer.
- Lysophosphatidylinositol (LPI) may significantly contribute to the development of colitis-associated cancer.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors